Celldex Therapeutics CLDX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -35,688.5%-17,101pp | -18,587.7%-8,732pp | -9,855.4%-5,802pp | -4,053.7%-1,180pp | -2,873.5%-94.6pp | |
| Net margin | -32,753.6%-16,016pp | -16,737.2%-8,101pp | -8,635.8%-5,189pp | -3,446.9%-1,081pp | -2,366.1%-117pp | |
| Returns | ||||||
| Return on equity | -48.9%-8.3pp | -40.6%-8.2pp | -32.4%-5.3pp | -27.2%-4.0pp | -23.2%+3.6pp | |
| Return on invested capital | -55.6%-8.6pp | -47%-8.1pp | -38.9%-5.6pp | -33.3%-2.6pp | -30.7%+4.2pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 8.9×-1.6× | 10.5×-2.5× | 13×-6.7× | 19.7×-2.0× | 21.7×+2.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.85-13.6% | $7.94-11.9% | $9.01-8.7% | $9.87-6.8% | $10.59-8.7% | |
| Valuation | ||||||
| Market capitalization | $2.11B+17.0% | $1.8B+5.1% | $1.72B+19.5% | $1.44B+19.3% | $1.2B-28.1% | |
| Price / sales | 2,438.2×+1,271× | 1,167.4×+507× | 660.7×+413× | 248.2×+88.8× | 159.4×-79.4× | |
| Price / book | 4.6×+1.2× | 3.4×+0.6× | 2.9×+0.7× | 2.2×+0.5× | 1.7×-0.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Celldex Therapeutics's ratios come from?
- Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
